Results 61 to 70 of about 4,121 (170)

Heterogeneity of Cancer‐Associated Fibroblasts and Precision Targeting Strategies for Cancer Therapy

Thoracic Cancer, Volume 17, Issue 11, June 2026.
CAFs orchestrate tumor immunosuppression through spatially organized ECM remodeling, cytokine signaling, and metabolic reprogramming. Targeting CAFs requires a shift from marker‐based depletion to functional state and niche‐specific intervention. ABSTRACT Immune checkpoint blockade (ICB) has transformed cancer therapy, but its effect is often limited ...
Yijie Wang, Guangyao Zhou, Pengpeng Zhang, Zhenfa Zhang, Lianmin Zhang   +4 more
wiley   +1 more source

Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity

Biomedicines, 2018
Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues
Daniel A. Vallera, Robert J. Kreitman
doaj   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

Advanced Healthcare Materials, Volume 15, Issue 18, 15 May 2026.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez, Miguel A. Moreno‐Gonzalez, Fernando Merwaiss, Nicole F. Steinmetz, José‐Antonio Daròs   +4 more
wiley   +1 more source

The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations

Toxins, 2017
Ribosome inactivating proteins (RIPs) form a class of toxins that was identified over a century ago. They continue to fascinate scientists and the public due to their very high activity and long-term stability which might find useful applications in the ...
Aleksander Rust, Lynda J. Partridge, Bazbek Davletov, Guillaume M. Hautbergue   +3 more
doaj   +1 more source

Correspondence of Basal Forebrain Resting‐State Functional Connectivity and Cerebral Glucose Metabolism Alterations With Neurotransmitter Maps in Alzheimer's Disease

CNS Neuroscience &Therapeutics, Volume 32, Issue 5, May 2026.
Altered functional connectivity of basal forebrain subregions (Ch1‐3, Ch4) and widespread cerebral hypometabolism were identified in Alzheimer's disease using simultaneous PET/MRI. Spatial correspondence with normative neurotransmitter receptor and transporter maps suggested that serotonergic and dopaminergic systems may contribute to AD‐related ...
Yujie He, Hanxiao Xue, Sheng Bi, Yan Wang, Xiaocao Liu, Yixia Li, Zhigeng Chen, Dongdong Rong, Bixiao Cui, Jie Ma, Shaozhen Yan, Jie Lu   +11 more
wiley   +1 more source

SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors

Toxins, 2018
SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest that anti-tumor immunity is ...
Yasmin Leshem, Emily M. King, Ronit Mazor, Yoram Reiter, Ira Pastan   +4 more
doaj   +1 more source

Secondary Necrosis Following Caspase‐Activation can Occur Independently of Gasdermin E

Advanced Science
Regulated necrosis is a known direct consequence of activation of the necroptosis‐ and pyroptosis‐ pathways, but may also result from apoptosis in a process referred to as secondary necrosis.
Shubhangi Gavali, Francesca Maremonti, Wulf Tonnus, Florian Gembardt, Marlena Nastassja Schlecht, Karolin Flade, Anne vonMässenhausen, Stephen W. G. Tait, Stefan R. Bornstein, Andreas Linkermann   +9 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies

Vaccines
Effective cancer therapies must address the tumor microenvironment (TME), a complex network of tumor cells and stromal components, including endothelial, immune, and mesenchymal cells. Durable outcomes require targeting both tumor cells and the TME while
Sahar Balkhi, Giorgia Bilato, Andrea De Lerma Barbaro, Paola Orecchia, Alessandro Poggi, Lorenzo Mortara   +5 more
doaj   +1 more source

T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications

Antibodies, 2013
Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells.
Maya Cohen, Yoram Reiter
doaj   +1 more source